Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Recurrent Prostate Cancer Men age ≥18 years who are fluent in English Histologically confirmed prostate adenocarcinoma Definitive therapy of primary prostate tumor completed. Definitive therapy can be prostatectomy, primary radiation therapy, brachytherapy, or cryotherapy. Salvage radiation after prostatectomy is allowed, if completed >60 days prior to study entry Prior surgical castration or active use of androgen deprivation therapy (ADT) alone, with expectation by the treating physician that patient would remain on ADT alone for upcoming 12 months, without escalating therapy. Prior ADT in the setting of definitive radiation therapy permitted Normal organ and marrow function function (labs within 30 days prior to study entry) as defined below: White blood cell count >3,500/mcL (or 3.5 (x103)) Platelet count >75,000/mcL (or 75 (x103)) Hemoglobin >9 g/dL Total bilirubin <2.5 X institutional upper limit of normal AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal Creatinine <2.5 X institutional upper limit of normal Able to ambulate (use of assist device is acceptable) Able to cooperate with study-related activities The effects of MGE on the developing human fetus are unknown. Men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative)  Symptomatic metastatic disease Any cancer treatment other than ADT within 30 days prior to study entry Documented rise in PSA (defined as rise of > 0.5 ng/mL) while on continuous ADT determined by PSA values, at least one of which must be during the 6 months prior to study entry PSA values must be at least 7 days apart Planned cessation of ADT or planned escalation of prostate cancer therapy within 12 months after study entry Ongoing use of any other investigational cancer-directed agents History of allergic reactions attributed to compounds of similar chemical or biologic composition to MGE Inability to swallow oral medications Malabsorption due to bowel resection or gastrointestinal disease leading to uncontrolled diarrhea, or persistent nausea or vomiting requiring daily antiemetic therapy for symptom management within the past week Uncontrolled intercurrent illness, including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements